BTA 0.00% 57.0¢ biota holdings limited

That's the fault of the FDA who failed Relenza and patients by...

  1. 3,045 Posts.
    That's the fault of the FDA who failed Relenza and patients by not accepting proposals for clinical trials using Relenza as an IV delivery... even the recommendation to the US president stating the FDA should accelerate a decision on IV relenza hasn't made an impact. It's time that the FDA gets a major look at, or the world looks for another agency. The FDA is simply not keeping up with the times.
 
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.